Oral vitamin D supplementation reduces the incidence of eucalcemic PTH elevation after surgery for primary hyperparathyroidism

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism, published as a controlled clinical trial.

This phenomenon may be due in part to an absolute or relative deficiency of vitamin D, which is under-recognized in patients with primary hyperparathyroidism.

Who Took Part

According to the abstract, 2005, patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

From September 1, 2004, to September 30, 2005, 86 consecutive patients underwent parathyroidectomy for primary sporadic hyperparathyroidism (psHPT).

The patients were segregated into 2 groups based on postoperative management.

How the Study Was Run

Group 1 was composed of 26 patients who received routine oral calcitriol and calcium carbonate postoperatively.

The 60 patients in the second group (group 2) received calcium carbonate postoperatively at the discretion of the primary surgeon.

What Was Measured

This phenomenon may be due in part to an absolute or relative deficiency of vitamin D, which is under-recognized in patients with primary hyperparathyroidism.

PubMed files the paper under topics including Calcitriol, Calcium, Calcium Carbonate, Calcium Channel Agonists, Hyperparathyroidism, Primary, Parathyroid Hormone and Parathyroidectomy.

What This Means in Plain Language

This is a controlled clinical trial of Parathyroid Hormone (PTH 1-84) in 2005, patients in people with hyperparathyroidism.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (Surgery), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.